Anzeige
Mehr »
Login
Mittwoch, 19.03.2025 Börsentäglich über 12.000 News von 692 internationalen Medien
Nachhaltig und revolutionär - Diese Innovation könnte der nächste Tesla-Moment für Investoren sein!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40ZZU | ISIN: NL0015002CX3 | Ticker-Symbol: QIA
Xetra
19.03.25
17:35 Uhr
36,540 Euro
+0,210
+0,58 %
1-Jahres-Chart
QIAGEN NV Chart 1 Jahr
5-Tage-Chart
QIAGEN NV 5-Tage-Chart
RealtimeGeldBriefZeit
36,30536,55518:26
36,30536,55518:26
PR Newswire
241 Leser
Artikel bewerten:
(1)

Zymo Research Corp.: Zymo Research Responds to Recent Court Ruling in Litigation with QIAGEN GmbH

Finanznachrichten News

IRVINE, Calif., March 19, 2025 /PRNewswire/ -- Zymo Research Corporation acknowledges the recent ruling, on March 14, 2025, by the United States District Court for the Central District of California in the ongoing litigation with QIAGEN GmbH. The Court has denied QIAGEN's Partial Motion to Dismiss and, in the alternative, to stay certain counterclaims brought by Zymo Research, including claims of patent unenforceability and antitrust violations.

Zymo Research Corp. Logo

Zymo Research is pleased with the Court's ruling and expects that its antitrust claims will be further vindicated through discovery and trial.

"We appreciate the Court's decision, which allows Zymo to defend our innovations." said Dr. Marc Van Eden, VP of Corporate Development.

Zymo Research remains confident in the novelty of its cfDNA MagicBead technology and looks forward to presenting its case as proceedings continue. This ruling reinforces Zymo Research's commitment to protecting scientific innovation and ensuring fair competition in the biotechnology sector. As proceedings continue, the company remains focused on delivering cutting-edge sample preparation technologies to the biomedical community worldwide.

About Zymo Research Corp.

Zymo Research, a privately owned biotech company founded in 1994, is a global leader in molecular tools for life sciences. Driven by the principle "The Beauty of Science is to Make Things Simple," Zymo Research is dedicated to developing innovative solutions that address complex scientific challenges.

Known also as The Epigenetics Company, Zymo Research offers a comprehensive range of technologies, including solutions for sample collection, DNA/RNA purification, library preparation, microbiomics, transcriptomics, epigenomics, genomics, and Next-Generation Sequencing (NGS) services.

In addition to its cutting-edge technologies, Zymo Research is committed to sustainability. By engineering environmentally friendly solutions, the company strives to reduce waste and contribute to a more sustainable future through scientific innovation.

For more information, please visit www.zymoresearch.com and follow on Facebook, LinkedIn, X (Twitter), and Instagram.

Logo - https://mma.prnewswire.com/media/364743/Zymo_Research_Corp_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/zymo-research-responds-to-recent-court-ruling-in-litigation-with-qiagen-gmbh-302405178.html

© 2025 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.